Literature DB >> 909316

Pleuropulmonary manifestations of ankylosing spondylitis.

E Rosenow, C V Strimlan, J R Muhm, R H Ferguson.   

Abstract

In published reports, the incidence of pleuropulmonary involvement in ankylosing spondylitis varies from 0 to 30%. A review of the records of 2,080 patients with ankylosing spondylitis disclosed 28 who had pleuropulmonary manifestations that we believe are typical of those associated with ankylosing spondylitis (an incidence of 1.3%). Among these 28 patients, the most common abnormality was upper lobe fibrobullous lesions. Five had aspergillomas and two had infections-one caused by Mycobacterium kansasii and one by Mycobacterium avium. Three patients had transient pleural effusion of an exudate with normal sugar content. Two had nonspecific pleuritis, found on pleural biopsy. Thoracotomy for aspergilloma was followed by bronchopleural fistula in one of two cases--approximately the ratio found in the literature.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 909316

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  34 in total

Review 1.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

2.  Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing.

Authors:  Abdellah El Maghraoui; Souad Chaouir; Ahmed Abid; Ahmed Bezza; Fatima Tabache; Lahsen Achemlal; Ali Abouzahir; Driss Ghafir; Victor Ohayon; Moulay Idriss Archane
Journal:  Clin Rheumatol       Date:  2004-02-24       Impact factor: 2.980

3.  Treatment for mycetoma with oral itraconazole in ankylosing spondylitis.

Authors:  Ilknur Basyigit; Ayten Yazici; Esra Kuslu Ucar; Hasim Boyaci; Fusun Yildiz
Journal:  Rheumatol Int       Date:  2011-12-31       Impact factor: 2.631

4.  Relation between chest expansion, pulmonary function, and exercise tolerance in patients with ankylosing spondylitis.

Authors:  L R Fisher; M I Cawley; S T Holgate
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

5.  Pulmonary involvement in ankylosing spondylitis.

Authors:  Percival D Sampaio-Barros; Elza Maria F P Cerqueira; Sílvio M Rezende; Lucimara Maeda; Roseneide A Conde; Verônica A Zanardi; Manoel Barros Bértolo; José Ribeiro de Menezes Neto; Adil M Samara
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

Review 6.  A patient with ankylosing spondylitis who presented with chronic necrotising aspergillosis: report on one case and review of the literature.

Authors:  Omer Nuri Pamuk; Orbay Harmandar; Birsen Tosun; Yener Yörük; Necati Cakir
Journal:  Clin Rheumatol       Date:  2004-12-23       Impact factor: 2.980

Review 7.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

8.  Bronchoalveolar lavage in ankylosing spondylitis.

Authors:  D Wendling; J C Dalphin; B Toson; A Depierre; M Guidet
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

9.  Pulmonary function and maximal transrespiratory pressures in ankylosing spondylitis.

Authors:  D Vanderschueren; M Decramer; P Van den Daele; J Dequeker
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

10.  Chronic necrotising pulmonary aspergillosis treated with itraconazole.

Authors:  J A Elliott; L J Milne; D Cumming
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.